In order to investigate an anti-tumorigenic MoA of Benz based on its mechanisms in Parkinson’s, we treated the tumoroids with an antimuscarinic (atropine), an antiparkinsonian agent of the antimuscarinic class trihexyphenidyl (THP), a DAT inhibitor (GBR-12935), a NET inhibitor [nisoxetine; a tricyclic antidepressant (TCA)], and a non-specific MAT inhibitor (amitriptyline; TCA). The gene discussed is SLC6A2; the disease is Parkinson disease.